Pembrolizumab versus Ipilimumab in Advanced Melanoma

Abstract

The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced melanoma. (Funded by Merck Sharp & Dohme; KEYNOTE-006 ClinicalTrials.gov number, NCT01866319.).

Keywords

PembrolizumabIpilimumabMedicineHazard ratioInternal medicineMelanomaGastroenterologyConfidence intervalOncologyImmunotherapyCancerCancer research

Affiliated Institutions

Related Publications

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares , Alexander Luft , David Vicente +20 more

In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in si...

2018 New England Journal of Medicine 3472 citations

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck , Delvys Rodríguez‐Abreu , Andrew Robinson +15 more

In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival...

2016 New England Journal of Medicine 9645 citations

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Edward B. Garon , Naiyer A. Rizvi , Rina Hui +24 more

Pembrolizumab had an acceptable side-effect profile and showed antitumor activity in patients with advanced non-small-cell lung cancer. PD-L1 expression in at least 50% of tumor...

2015 New England Journal of Medicine 6054 citations

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Leena Gandhi , Delvys Rodríguez‐Abreu , Shirish M. Gadgeel +26 more

In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a plat...

2018 New England Journal of Medicine 6245 citations

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

James Larkin , Vanna Chiarion‐Sileni , René González +28 more

BACKGROUND Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advance...

2019 New England Journal of Medicine 3500 citations

Publication Info

Year: 2015
Type: article
Volume: 372
Issue: 26
Pages: 2521-2532
Citations: 5661
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Pembrolizumab versus Ipilimumab in Advanced Melanoma

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

5661

OpenAlex

Cite This

APA Style

                            
                                
                                    Caroline Robert, 
                                
                                    Jacob Schachter, 
                                
                                    Georgina V. Long
                                
                                et al.
                            
                            (2015). 
                            Pembrolizumab versus Ipilimumab in Advanced Melanoma. 
                            New England Journal of Medicine
                            , 372
                            (26)
                            , 2521-2532.
                            https://doi.org/10.1056/nejmoa1503093
                        

Identifiers

DOI: 10.1056/nejmoa1503093